NEW YORK (GenomeWeb) – Illumina's second quarter revenues rose 21 percent year over year, the company announced after the close of the market on Tuesday, but fell short of Wall Street's consensus estimate on the top line.

The firm recognized total revenues of $539.4 million for the three months ended June 30, compared to $447.6 million in the second quarter 2014. Analysts, on average, had expected revenues of $541.8 million. On a constant currency basis, Illumina's revenues rose 25 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.